Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Controlling immune responses in autoimmunity and to biotherapeutics is an unmet need. In hemophilia, for example, up to one third of patients receiving therapeutic factor VIII (FVIII) infusions develop neutralizing Abs termed “inhibitors.” To address this problem in a mouse model of hemophilia A, we used an Ag-specific regulatory T cell (Treg) approach in which we created a novel B cell–targeting chimeric receptor composed of an FVIII Ag domain linked with the CD28-CD3ζ transmembrane and signaling domains. We termed these “BAR” for B cell–targeting Ab receptors. CD4+CD25hiCD127low human Tregs were retrovirally transduced to express a BAR containing the immunodominant FVIII C2 or A2 domains (C2- and A2-BAR). Such BAR-Tregs specifically suppressed the recall Ab response of spleen cultures from FVIII-immunized mice in vitro and completely prevented anti-FVIII Ab development in response to FVIII immunization. Mechanistic studies with purified B cells and T cells from tolerized or control recipients demonstrated that the FVIII-specific B cells were directly suppressed or anergized, whereas the T cell response remained intact. Taken together, we report in this study a successful proof-of-principle strategy using Ag-expressing Tregs to directly target specific B cells, an approach which could be adapted to address other adverse immune responses as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type 1 diabetes immunotherapy using polyclonal regulatory T cells
Bluestone, J. A., Buckner, J. H., Fitch, M., Gitelman, S. E., Gupta, S., Hellerstein, M. K., Herold, K. C., Lares, A., Lee, M. R., Li, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4134 · Cited by 1,033 · cited 2×
“One major difference in our current report is that instead of engineering cytotoxic T cells, we focused on developing Ag-specific hTregs to increase the efficacy of polyclonal Treg therapy used in recent clinical trials (3).”
BackgroundPolymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408686111 · Cited by 441 · cited 1×
“Experimental FVIII tolerance induction has also been achieved through coadministration of FVIII with rapamycin (28, 29) or with IL-2/IL-2 mAb complexes (30).”
MethodSelf-citationYoon, J., Schmidt, A., Zhang, A.-H., Königs, C., Kim, Y. C., & Scott, D. W. (2017) · Blood · doi:10.1182/blood-2016-07-727834 · Cited by 150 · cited 14×
“To construct FVIII-C2-BAR, the scFv region of the ANS8 CAR (10) was replaced with FVIII C2 domain, and the resultant (leader sequence)-C2-(G4S linker)-CD28-CD3z cDNA was codon optimized and synthesized by GenScript USA (Piscataway, NJ) and ligated into pRetroX-IRES-ZsGreen1 (Clontech Laboratories, Mountain View, CA) r…”
BackgroundMethodResultInfluentialSelf-citationDu, L. M., Nurden, P., Nurden, A. T., Nichols, T. C., Bellinger, D. A., Jensen, E. S., Haberichter, S. L., Merricks, E., Raymer, R. A., Fang, J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3773 · Cited by 119
Research works printed but not linked: 41
- Vignali, 2008, How regulatory T cells work, Nat. Rev. Immunol., 8, 523, 10.1038/nri2343 · DOI · Paper page
- Bluestone, 2005, Regulatory T-cell therapy: is it ready for the clinic?, Nat. Rev. Immunol., 5, 343, 10.1038/nri1574 · DOI · Paper page
- Tang, 2012, CD4(+)Foxp3(+) regulatory T cell therapy in transplantation, J. Mol. Cell Biol., 4, 11, 10.1093/jmcb/mjr047 · DOI · Paper page
- Brunstein, 2013, Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation, Biol. Blood Marrow Transplant., 19, 1271, 10.1016/j.bbmt.2013.06.004 · DOI · Paper page
- Brusko, 2010, Human antigen-specific regulatory T cells generated by T cell receptor gene transfer, PLoS One, 5, e11726, 10.1371/journal.pone.0011726 · DOI · Paper page
- MacDonald, 2016, Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor, J. Clin. Invest., 126, 1413, 10.1172/JCI82771 · DOI · Paper page
- Ettinger, 2009, Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses, Blood, 114, 1423, 10.1182/blood-2009-01-200725 · DOI · Paper page
- Kim, 2015, Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses, Blood, 125, 1107, 10.1182/blood-2014-04-566786 · DOI · Paper page
- Qian, 2000, Prevention and treatment of factor VIII inhibitors in murine hemophilia A, Blood, 95, 1324, 10.1182/blood.V95.4.1324.004k25_1324_1329 · DOI · Paper page
- Bi, 1995, Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A, Nat. Genet., 10, 119, 10.1038/ng0595-119 · DOI · Paper page
- Kim, 2012, Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion, Blood, 119, 2810, 10.1182/blood-2011-09-377895 · DOI · Paper page
- Hausl, 2004, Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders, Blood, 104, 115, 10.1182/blood-2003-07-2456 · DOI · Paper page
- Zhang, 2011, Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice, Blood, 117, 2223, 10.1182/blood-2010-06-293324 · DOI
- Lollar, 2004, Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX, J. Thromb. Haemost., 2, 1082, 10.1111/j.1538-7836.2004.00802.x · DOI
- Scandella, 1988, Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli, Proc. Natl. Acad. Sci. USA, 85, 6152, 10.1073/pnas.85.16.6152 · doi:10.1073/pnas.85.16.6152
- Lei, 2005, Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins, Blood, 105, 4865, 10.1182/blood-2004-11-4274 · DOI · Paper page
- Bray, 1993, Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the multi-center hemophilia cohort study, Am. J. Hematol., 42, 375, 10.1002/ajh.2830420408 · DOI · Paper page
- Evans, 1998, Development of autoantibodies and factor VIII inhibitor in an HIV-infected haemophiliac following treatment with combination anti-retroviral therapy, Br. J. Haematol., 102, 1382, 10.1046/j.1365-2141.1998.00985.x · doi:10.1046/j.1365-2141.1998.00985.x
- Matsui, 2009, A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells, Blood, 114, 677, 10.1182/blood-2009-03-202267 · DOI · Paper page
- Sack, 2012, Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy, PLoS One, 7, e37671, 10.1371/journal.pone.0037671 · DOI · Paper page
- Lei, 2005, Tolerance induction via a B-cell delivered gene therapy-based protocol: optimization and role of the Ig scaffold, Cell. Immunol., 235, 12, 10.1016/j.cellimm.2005.06.007 · DOI
- Peng, 2009, Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy, Blood, 114, 4373, 10.1182/blood-2009-05-217315 · DOI · Paper page
- Waters, 2009, Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response, Blood, 113, 193, 10.1182/blood-2008-04-151597 · DOI · Paper page
- Oliveira, 2013, Adjuvant facilitates tolerance induction to factor VIII in hemophilic mice through a Foxp3-independent mechanism that relies on IL-10, Blood, 121, 3936, 10.1182/blood-2012-09-457135 · DOI
- Moghimi, 2011, Induction of tolerance to factor VIII by transient co-administration with rapamycin, J. Thromb. Haemost., 9, 1524, 10.1111/j.1538-7836.2011.04351.x · DOI · Paper page
- Liu, 2014, Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII, J. Thromb. Haemost., 12, 921, 10.1111/jth.12576 · DOI
- Wang, 2015, Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells, Blood, 125, 2418, 10.1182/blood-2014-08-597070 · DOI · Paper page
- Sarkar, 2014, Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia, Mol. Ther. Methods Clin. Dev., 1, 14030, 10.1038/mtm.2014.30 · DOI · Paper page
- Hausl, 2005, High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors, Blood, 106, 3415, 10.1182/blood-2005-03-1182 · DOI · Paper page
- Ellebrecht, 2016, Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease, Science, 353, 179, 10.1126/science.aaf6756 · DOI · Paper page
- Bystry, 2001, B cells and professional APCs recruit regulatory T cells via CCL4, Nat. Immunol., 2, 1126, 10.1038/ni735 · DOI · Paper page
- Zhao, 2006, Activated CD4+CD25+ T cells selectively kill B lymphocytes, Blood, 107, 3925, 10.1182/blood-2005-11-4502 · DOI · Paper page
- Gotot, 2012, Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo, Proc. Natl. Acad. Sci. USA, 109, 10468, 10.1073/pnas.1201131109 · DOI
- Gondek, 2005, Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism, J. Immunol., 174, 1783, 10.4049/jimmunol.174.4.1783 · DOI · Paper page
- Ashley, 2009, Cutting edge: responder T cells regulate human DR+ effector regulatory T cell activity via granzyme B, J. Immunol., 183, 4843, 10.4049/jimmunol.0900845 · DOI
- Tran, 2009, Analysis of adhesion molecules, target cells, and role of IL-2 in human FOXP3+ regulatory T cell suppressor function, J. Immunol., 182, 2929, 10.4049/jimmunol.0803827 · DOI
- Klein, 2003, In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro, Proc. Natl. Acad. Sci. USA, 100, 8886, 10.1073/pnas.1533365100 · DOI · Paper page
- Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751 · DOI · Paper page
- Sakemura, 2016, A Tet-on inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration, Cancer Immunol. Res., 4, 658, 10.1158/2326-6066.CIR-16-0043 · DOI · Paper page
- Foster, 2017, Regulated expansion and survival of chimeric antigen receptor-modified T cells using small molecule-dependent inducible MyD88/CD40, Mol. Ther., 25, 2176, 10.1016/j.ymthe.2017.06.014 · DOI · Paper page
- Straathof, 2005, An inducible caspase 9 safety switch for T-cell therapy, Blood, 105, 4247, 10.1182/blood-2004-11-4564 · DOI · Paper page
Cited by
Next-generation regulatory T cell therapy
Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A., & Tang, Q. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0041-4 · Cited by 476
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
De Paula Pohl, A., Schmidt, A., Zhang, A.-H., Maldonado, T., Königs, C., & Scott, D. W. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104222 · Cited by 91
Self-citationParvathaneni, K., & Scott, D. W. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018018556 · Cited by 56
“Female E16 mice (n 5 5 per group, age matched) were adoptively transferred with 1 3 106 fluorescence-activated cell sorted syngeneic CD8 T cells expressing either A2/C2- or OVA-BAR.”
BackgroundSelf-citationMateos-Hernández, L., Risco-Castillo, V., Torres-Maravilla, E., Bermúdez-Humarán, L. G., Alberdi, P., Hodžić, A., Hernández-Jarguin, A., Rakotobe, S., Galon, C., Devillers, E., et al. (2020) · Vaccines · doi:10.3390/vaccines8020285 · Cited by 46
“Among the regulatory functions of Tregs is the suppression of production of antigen-specific Abs [49].”
Background
Metadata
- Authors
- Zhang, A.-H., Yoon, J., Kim, Y. C., & Scott, D. W.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-09-01
- Volume
- 201
- Issue
- 5
- Pages
- 1434-1441
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2883538026
- Cited by
- 63
- References
- 4
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.